About Duchenne

The Duchenne gene is found on the X-chromosome; therefore, it affects mostly males. In rare cases, it also affects females. It affects approximately 1 in every 5,000 live male births. There are approximately 15,000 patients diagnosed with Duchenne alive today in the United States.

Duchenne has no cure.

Duchenne is a progressive neuromuscular disorder that causes a loss of motor, pulmonary, and cardiac function. It is caused by a mutation in the gene that encodes for dystrophin, a lubricating protein supports muscle fiber strength. When dystrophin is missing in the body, muscle cells are easily damaged, which causes progressive muscle weakness in the entire body.

Children with Duchenne are born seemingly healthy and decline over time, typically losing their ability to walk around the age of 12 and succumbing to the disease in their early to mid-twenties.

Duchenne can be passed from parent to child, but approximately 35% of cases occur because of a random spontaneous mutation. In other words, it can affect anyone.

To learn about FDA approved drugs for Duchenne muscular dystrophy, please visit our Treatment and Care page.

For more information on Duchenne, or to learn how to support Jett Foundation’s mission of empowering individuals and families that are impacted by Duchenne, please explore our website or contact [email protected].

Diagnosis

We have gathered helpful resources and information for those on a Duchenne journey, in both its highs and lows.

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet.

Treatment & Care

Read more about FDA approved Duchenne treatments.

Latest Duchenne News

May 20, 2026
On May 20, 2026, Dyne Therapeutics, Inc. announced the initiation of the Phase 3 FORZETTO trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy...
May 14, 2026
On May 14, 2026 REGENXBIO Inc. announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, a potential...
May 11, 2026
On May 7, 2026, Solid Biosciences Inc. announced that the first participant has been dosed in IMPACT DUCHENNE, the Company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003...

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA